Mustang Bio lists on NASDAQ

Cancer company Mustang Bio Inc. (NASDAQ:MBIO) began trading on NASDAQ Tuesday without raising any money. The company opened the day at $9.50 and closed at $9.80 with a market cap of about $247 million.

Early next year, Mustang plans to report data from Phase I trials of its MB-101, a chimeric antigen receptor (CAR) T cell therapy targeting IL-13 receptor alpha 2 (IL-13RA2; IL-13R; CD213A2), to treat glioblastoma; and MB-102, a CAR T cell therapy targeting IL-3 receptor alpha (CD123), to treat acute myelogenous leukemia (AML). Mustang licensed the CAR T technology from City of Hope (Duarte, Calif.)...